*To the Editor*:

Rapidly progressing hypoxemia and acute respiratory distress syndrome were commonly observed in patients with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) viral pneumonia \[[@C1]\]. Although several severity scores including Pneumonia Severity Index (PSI) \[[@C2]\], CURB-65 and CRB-65 (confusion, (urea \>7 mmol·L^−1^), respiratory rate ≥30 breaths·min^−1^, blood pressure \<90 mmHg (systolic) ≤60 mmHg (diastolic), age ≥65 years), \[[@C3]\], A-DROP \[[@C4]\] and SMART-COP \[[@C5]\] have been developed to identify community acquired pneumonia (CAP) patients at high risk and offer therapeutic advice, the underestimation of risk of death from viral pneumonia in these scores has been reported by previous studies \[[@C6], [@C7]\]. The National Early Warning Score 2 (NEWS2) was developed by National Health Service (NHS) England \[[@C8]\] and, along with quick sequential organ failure assessment score (qSOFA), was proposed as a candidate for prognostic prediction for severe coronavirus disease 2019 (COVID-19) in the situation of limited medical source \[[@C9]\]. The aim of this study was to compare the accuracy of current score rules in hospitalised patients with COVID-19 pneumonia for predicting the risk of death and evaluate feasibility in improving medical decisions by adopting appropriate scores in clinical practice.

Adult inpatients who were diagnosed as COVID-19 according to World Health Organization (WHO) interim guidance and died/were discharged between 29 December 2019 and 15 February 2020 in Jin Yin-tan Hospital (Wuhan city, China) were retrospectively enrolled in this study. After excluding 689 patients who were still hospitalised as of 15 February 2020, 42 patients with missing key data in their medical records which was essential in scoring, and six deaths within 24 h after admission, we were left with 654 cases, including 521 survivors and 133 non-survivors with intact information to complete calculation of all above scores.

The study was approved by the Research Ethics Commission of Jin Yin-tan Hospital (KY-2020-01.01) and the informed consent was waived by the Ethics Commission.

Information were obtained from electronic medical records. A standardised data collection form (a modified version of the WHO/International Severe Acute Respiratory and Emerging Infection Consortium case record form for severe acute respiratory infections) was used for data extraction. The score on admission of each patient was noted for eight severity score rules, including A-DROP, CURB-65, PSI, SMART-COP, NEWS2, CRB-65 and qSOFA. A-DROP was a modified version of the CURB-65 score rules, including the integrated evaluation of age, dehydration, oxygen saturation measured by pulse oximetry (*S*~pO~2~~) or arterial oxygen saturation (*P*~aO~2~~), consciousness and blood pressure \[[@C4]\]. Two researchers were responsible for the accuracy of raw data, and a third party was necessary if doubts existed.

Next-generation sequencing or real-time RT-PCR methods were performed to detect SARS-CoV-2 of respiratory specimens. The PCR re-examination was conducted by throat swab specimens after clinical remission of symptoms. A patient was allowed to be discharged if they achieved clinical improvement and had two throat swab samples negative for SARS-CoV-2 RNA obtained at least 24 h apart.

The illness severity of COVID-19 was defined according to Chinese management guidelines for COVID-19 (version 6.0) \[[@C10]\]. The performance of sensitivity, specificity, or area under the curve (AUC) was defined as poor with a value \<0.5, low with a value between 0.5 and 0.7, moderate with a value between 0.7 and 0.85, and excellent with a value \>0.85.

We assessed the predictive performance of A-DROP, CURB-65, PSI, SMART-COP, NEWS2, CRB-65 and qSOFA for in-hospital death by describing receiver operating characteristic curves for each score. Sensitivity, specificity, positive predictive value, negative predictive value and their 95% CIs were calculated. The AUC and 95% CI were estimated to determine the discrimination and net reclassification improvement and integrated discrimination improvement were also estimated to assess the improvement of other scores compared with A-DROP score in death prediction.

A two-sided α \<0.05 was considered statistically significant for all statistical tests. Statistical analyses were performed by the SAS software, version 9.4 (SAS Institute Inc.), unless otherwise indicated.

Among all seven scores that were determined by patients\' information on admission, A-DROP presented the highest discrimination (AUC 0.87; 95% CI 0.84--0.90), following by CURB-65 (AUC 0.85; 95% CI 0.81--0.89), PSI (AUC 0.85; 95% CI 0.81--0.88), SMART-COP (AUC 0.84; 95% CI 0.80--0.88), NEWS2 (AUC 0.81; 95% CI 0.77--0.85), CRB-65 (AUC 0.80; 95% CI 0.76--0.84), and qSOFA (AUC 0.73; 95% CI 0.69--0.78) in predicting in-hospital death. Taking A-DROP as reference, the AUC contrast showed an insignificant difference between A-DROP and CURB-65 or A-DROP and PSI, while the discrimination of A-DROP was significantly better than any other score rules. Similar differences were also observed with respect to INR and IDI. The positive differences of INR and IDI indicated the discrimination of A-DROP was improved compared with other scores ([table 1](#TB1){ref-type="table"}).

###### 

The comparison of different clinical prediction rules

  **Variable**     **AUC (95% CI)**    **p-value**   **Cut-off value**   **Sensitivity (95% CI)**   **Specificity (95% CI)**   **PPV (95% CI)**    **NPV (95% CI)**    **NRI**   **IDI**
  --------------- ------------------- ------------- ------------------- -------------------------- -------------------------- ------------------- ------------------- --------- ---------
  **A-DROP**       0.87 (0.84--0.90)       Ref               2              0.80 (0.73--0.87)          0.86 (0.83--0.89)       0.60 (0.52--0.67)   0.94 (0.92--0.96)     Ref       Ref
  **CURB-65**      0.85 (0.81--0.89)     0.2259              2              0.63 (0.55--0.71)          0.91 (0.89--0.93)       0.65 (0.56--0.73)   0.91 (0.88--0.93)    0.12      0.06
  **PSI**          0.85 (0.81--0.88)     0.1876              3              0.77 (0.70--0.84)          0.81 (0.78--0.84)       0.50 (0.44--0.57)   0.93 (0.91--0.96)    0.08      0.07
  **SMART-COP**    0.84 (0.80--0.88)     0.0405              2              0.83 (0.77--0.89)          0.76 (0.72--0.80)       0.46 (0.40--0.53)   0.94 (0.92--0.97)    0.08      0.11
  **NEWS2**        0.81 (0.77--0.85)     0.0045              5              0.79 (0.72--0.86)          0.69 (0.65--0.73)       0.40 (0.34--0.46)   0.93 (0.90--0.95)    0.17      0.16
  **CRB-65**       0.80 (0.76--0.84)     0.0001              1              0.83 (0.77--0.89)          0.69 (0.65--0.73)       0.40 (0.34--0.46)   0.94 (0.92--0.96)    0.15      0.15
  **qSOFA**        0.73 (0.69--0.78)    \<0.0001             1              0.82 (0.75--0.89)          0.57 (0.53--0.61)       0.33 (0.28--0.38)   0.93 (0.90--0.95)    0.27      0.24

AUC: area under the curve; PPV: positive predictive value; NPV: negative predictive value; NRI: net reclassification improvement; IDI: integrated discrimination improvement; C(U)RB-65: confusion, (urea \>7 mmol·L^−1^), respiratory rate ≥30 breaths·min^−1^, blood pressure \<90 mmHg (systolic) ≤60 mmHg (diastolic), age ≥65 years; PSI: pneumonia severity index; NEWS2: national early warning score 2; qSOFA: quick sequential organ failure assessment.

The sensitivity of A-DROP≥2, PSI≥3, SMART-COP≥2, NEWS2≥5, CRB-65≥1 and qSOFA≥1 were moderate, whilst that of CURB-65≥2 was low for identifying patients at risk of death. The specificity of identifying survivors for CURB-65≥2 was excellent (0.91, 95% CI 0.89--0.93), followed by A-DROP≥2, PSI≥3 and SMART-COP≥2, whilst the specificity for the rest of the scores were low ([table 1](#TB1){ref-type="table"}).

The accuracy of a variety of severity scores to predict in-hospital death in 654 laboratory confirmed COVID-19 patients admitted to hospital was examined in our study and we found A-DROP was a priority clinical tool for predicting the risk of death for patients with COVID-19 pneumonia, compared with other score systems.

A-DROP, a modified version of CURB-65 \[[@C4]\], showed better accuracy of in-hospital death prediction compared to other current widely used CAP-specific tools. According to previous studies, ARDS was common in severe COVID-19 pneumonia \[[@C11], [@C12]\]. The rapid progression of diffuse bilateral ground-glass opacities on a computed tomography scan and massive alveolar damage with focal haemorrhage, cellular fibromyxoid exudates and hyaline membrane formation in lung histological examination also suggested a close association between COVID-19 pneumonia and low *P*~aO~2~~/inspiratory oxygen fraction \[[@C13]\]. The modification of more accurate respiratory function evaluation (*S*~pO~2~~ \<90%/*P*~aO~2~~ \<60 mmHg in A-DROP *versus* respiratory rate ≥30 breaths per min in CURB-65) could be one reason for improvement in the discrimination of A-DROP. Another reason may be the modification in age (male \>70 years/female \>75 years in A-DROP *versus* \>65 years in CURB-65). The median age of non-survivors with COVID-19 was reported to be 69 years \[[@C14]\]. Besides, the heavier weight on underlying disease instead of respiratory function in PSI may lead to an underestimated severity of COVID-19 pneumonia, compared with A-DROP.

NEWS2 score assesses respiration rate, oxygen saturations, systolic blood pressure, heart rate, temperature and level of consciousness, which were easier for use in the emergency department \[[@C8]\]. It proved to be a valid tool for early identification in acutely ill patients with infection \[[@C8]\]. However, without considering the scale of respiratory support therapy, the category of oxygen saturation in NEWS2 score may not reflect the severity of hypoxaemia and lung injury accurately. Lacking markers of other organ dysfunction may be also the reason for its unsatisfying performance.

There are some limitations in the study. First, this is a single-centre study and the intrinsic defects of retrospective studies were unavoidable, for example, scores at different time-points were unavailable, so we could hardly evaluate disease severity dynamically. Secondly, only patients discharged or died were included in this study and those still being hospitalised were excluded. Thirdly, it is unable to evaluate SOFA\'s performance as results of arterial blood gas tests were absent for most patients in this study.

In summary, A-DROP is a reliable tool for risk stratification of death in COVID-19 hospitalised patients on admission.
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